<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Beta-cells possess inherent mechanisms to adapt to <z:e sem="disease" ids="C1257763" disease_type="Disease or Syndrome" abbrv="">overnutrition</z:e> and the prevailing concentrations of <z:chebi fb="105" ids="17234">glucose</z:chebi>, fatty acids, and other fuels to maintain <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis </plain></SENT>
<SENT sid="1" pm="."><plain>However, this is balanced by potentially harmful actions of the same nutrients </plain></SENT>
<SENT sid="2" pm="."><plain>Both <z:chebi fb="105" ids="17234">glucose</z:chebi> and fatty acids may cause good/adaptive or evil/toxic actions on the beta-cell, depending on their concentrations and the time during which they are elevated </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> high <z:chebi fb="105" ids="17234">glucose</z:chebi> dramatically influences beta-cell <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism via substrate availability, changes in the activity and expression of enzymes of <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism, and modifications in the expression level of key transcription factors </plain></SENT>
<SENT sid="4" pm="."><plain>We discuss here the emerging view that beta-cell "glucotoxicity" is in part indirectly caused by "lipotoxicity," and that beta-cell abnormalities will become particularly apparent when both <z:chebi fb="105" ids="17234">glucose</z:chebi> and circulating fatty acids are high </plain></SENT>
<SENT sid="5" pm="."><plain>We support the concept that elevated <z:chebi fb="105" ids="17234">glucose</z:chebi> and fatty acids synergize in causing toxicity in islets and other organs, a process that may be instrumental in the pleiotropic defects associated with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>The mechanisms by which <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> alter insulin secretion are discussed and a model of beta-cell "glucolipotoxicity" that implicates alterations in beta-cell <z:chebi fb="0" ids="15531">malonyl-CoA</z:chebi> concentrations; peroxisome proliferator-activated receptor-alpha and -gamma and <z:chebi fb="0" ids="15889">sterol</z:chebi> regulatory element binding protein-1c expression; and <z:chebi fb="23" ids="18059">lipid</z:chebi> partitioning is proposed </plain></SENT>
</text></document>